{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:35:23Z","timestamp":1761100523233},"reference-count":38,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2001,12,21]],"date-time":"2001-12-21T00:00:00Z","timestamp":1008892800000},"content-version":"vor","delay-in-days":309,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2001,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p> <jats:italic>Background:<\/jats:italic> Interferon\u2010\u03b1 (IFN) is known to promote graft\u2010versus\u2010host disease (GVHD) after allogeneic bone marrow transplantation (allo BMT). This property may also be used to enhance a graft\u2010versus\u2010leukaemia effect (GVL) after donor leucocyte infusion (DLI), a mode of therapy increasingly offered to patients relapsing after allo BMT.<\/jats:p><jats:p> <jats:italic>Aim:<\/jats:italic> The aims of the present study were to examine the efficacy and toxicity of IFN therapy administered after granulocyte colony\u2010stimulating factor (G\u2010CSF)\u2010stimulated blood cells given as DLI in patients with acute myeloid leukaemia (AML), chronic myeloid leukaemia (CML), acute lymphoblastic leukaemia (ALL), acute undifferentiated leukaemia (AUL) and multiple myeloma relapsing after allo BMT.<\/jats:p><jats:p> <jats:italic>Methods:<\/jats:italic> Between October 1996 and September 1999, 27 patients (16 AML, four ALL, three CML, three multiple myeloma, one AUL) who relapsed after allo BMT were treated with chemotherapy followed by DLI, collected after G\u2010CSF stimulation in all but two cases. Subsequently, IFN was given to patients without significant GVHD or rapidly progressive disease. The outcome after DLI with regard to remission rate, disease\u2010free survival and GVHD was analysed.<\/jats:p><jats:p> <jats:italic>Results:<\/jats:italic> Eighteen patients received IFN following DLI, 14 of whom developed significant GVHD (grade II\u2013IV acute or extensive chronic); thereafter, GVHD resolved with cessation of IFN alone in four patients, but 10 required systemic immunosuppression. Twenty\u2010three patients were given chemotherapy and DLI as initial treatment of relapse; 10 achieved complete remission (CR), in four patients this was only after the onset of GVHD. The other four patients received chemotherapy and DLI as a consolidation of a chemotherapy\u2010induced remission. The CR was durable only in patients with CML (3 of 3) and AML (4 of 8).<\/jats:p><jats:p> <jats:italic>Conclusions:<\/jats:italic> Treatment with IFN induced GVHD in the majority of patients receiving DLI. The induction of GVHD and GVL by this approach produced excellent results in patients with CML and modest results in AML, but appeared to be less effective in myeloma and ALL. (Intern Med J 2001; 31: 15\u201322)<\/jats:p>","DOI":"10.1046\/j.1445-5994.2001.00013.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T02:14:55Z","timestamp":1047435295000},"page":"15-22","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Chemotherapy and granulocyte colony stimulating factor\u2010mobilized blood cell infusion followed by interferon\u2010\u03b1 for relapsed malignancy after allogeneic bone marrow transplantation"],"prefix":"10.1111","volume":"31","author":[{"given":"A.","family":"Grigg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Kannan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. P.","family":"Schwarer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Szer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,21]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.433"},{"key":"e_1_2_6_3_2","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1182\/blood.V86.4.1261.bloodjournal8641261","article-title":"Adoptive immunotherapy evaluating escalating doses for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft versus leukemia responses from graft versus host disease.","volume":"86","author":"Mackinnon S","year":"1995","journal-title":"Blood"},{"key":"e_1_2_6_4_2","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","article-title":"Graft\u2010versus\u2010leukemia effect of donor lymphocyte transfusion in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party for Chronic Leukaemia.","volume":"86","author":"Kolb H\u2010J","year":"1995","journal-title":"Blood"},{"key":"e_1_2_6_5_2","first-page":"3306","article-title":"Treatment with recombinant interferon (alpha\u20102b) early after bone marrow transplantation in patients at high risk for relapse.","volume":"78","author":"Klingemann HG","year":"1991","journal-title":"Blood"},{"key":"e_1_2_6_6_2","first-page":"759","article-title":"Feasibility and toxicity of interferon maintenance therapy after allogeneic BMT for multiple myeloma: a pilot study of the EBMT.","volume":"17","author":"Samson D","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_6_7_2","first-page":"10","article-title":"Interferon therapy of lymphoproliferative disorders.","volume":"23","author":"Foon KA.","year":"1986","journal-title":"Semin Hematol"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198604243141701"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00922756"},{"key":"e_1_2_6_10_2","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1182\/blood.V72.3.1048.bloodjournal7231048","article-title":"Modulation of the expression of major histocompatibility antigens on splenic hairy cells: differential effect upon in vitro treatment with alpha\u20102b interferon, gamma\u2010interferon, and interleukin\u20102.","volume":"72","author":"Gressler VH","year":"1988","journal-title":"Blood"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-107-6-809"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.4.671"},{"key":"e_1_2_6_13_2","first-page":"1269","article-title":"Long\u2010term results following treatment of newly\u2010diagnosed acute myelogenous leukemia with continuous infusion high\u2010dose cytosine arabinoside.","volume":"8","author":"Ghaddar HM","year":"1994","journal-title":"Leukemia"},{"key":"e_1_2_6_14_2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood.V75.1.27.27","article-title":"Etoposide in acute non\u2010lymphocytic leukemia.","volume":"75","author":"Bishop JF","year":"1990","journal-title":"Blood"},{"issue":"1","key":"e_1_2_6_15_2","first-page":"173a","article-title":"Update of HYPER\u2010CVAD program in newly diagnosed adult acute lymphoblastic leukaemia.","volume":"86","author":"Kantarjian H","year":"1995","journal-title":"Blood"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830330203"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-197410000-00001"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.1.212"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199909058497"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.4993.626"},{"key":"e_1_2_6_21_2","first-page":"61","article-title":"Principles of graft\u2010vs.\u2010leukemia reactivity.","volume":"1","author":"Truitt RL","year":"1995","journal-title":"Biol Blood Marrow Transplant"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198106183042507"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)92009-9"},{"key":"e_1_2_6_24_2","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","article-title":"Graft\u2010versus\u2010leukemia reactions after bone marrow transplantation.","volume":"75","author":"Horowitz MM","year":"1990","journal-title":"Blood"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-108-6-806"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)92879-9"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199007000-00038"},{"key":"e_1_2_6_28_2","first-page":"391","article-title":"Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft\u2010versus\u2010leukaemia effect following abrupt discontinuation of immunosuppression.","volume":"10","author":"Collins Rh","year":"1992","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.62650.x"},{"key":"e_1_2_6_30_2","first-page":"109","article-title":"Donor leucocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT.","volume":"11","author":"Szer J","year":"1993","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199401133300204"},{"key":"e_1_2_6_32_2","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1182\/blood.V90.10.4206","article-title":"Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation.","volume":"90","author":"Lokhorst HM","year":"1997","journal-title":"Blood"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.262674.x"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1080\/00313029600169523"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701387"},{"key":"e_1_2_6_36_2","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1182\/blood.V89.9.3113","article-title":"Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: lack of residual donor hemopoiesis predicts aplasia.","volume":"89","author":"Kiel F","year":"1997","journal-title":"Blood"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701385"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1089\/scd.1.1998.7.449"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701403"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1445-5994.2001.00013.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1445-5994.2001.00013.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T13:24:56Z","timestamp":1697635496000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1445-5994.2001.00013.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,2,15]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,2,15]]}},"alternative-id":["10.1046\/j.1445-5994.2001.00013.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1445-5994.2001.00013.x","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,2,15]]},"assertion":[{"value":"2001-12-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}